Researchers at Brigham and Women’s Hospital, in a cross-sectional analysis of 1,446 Medicare Part D formularies to determine the presence and utilization of angiotensin receptor blockers (ARBs), found that people who have been in a Medicare supplement plan will pay more for these drugs when they join a Part D plan.
Also, any savings from lower copayments under Part D may be offset by the monthly premium and by more expensive cost-sharing when beneficiaries reach the “doughnut hole.”
Depending on how broadly a formulary defines the class of renin-angiotensin-aldosterone system inhibitors, of which ARBs and angiotensin-converting enzyme (ACE) inhibitors are a part, formularies could contain two ACE inhibitors and no ARBs. This could be detrimental to patients who cannot tolerate ACE inhibitors.
“The ARBs valsartan and losartan are the most commonly found ARBs on formularies, which will limit therapeutic substitution,” says Walid F. Gellad, MD, lead author of the study. “Nonetheless, there will be some patients who will have to switch ARBs when they join Part D,” says Gellad.
Under Part D, the average prescription cost-sharing for each of the ARBs ranges from $28 to $47. Average copayments were more than twice as high for the Part D plans, compared to commercial copayments. About one-half of patients who take ARBs will be affected by the doughnut hole and there will be no generic ARBs until at least 2009, when the patent on losartan (Cozaar) expires.
Paying more under Part D
People who paid the whole cost of their ARB prescriptions before Part D may pay less on average if they join a Medicare Part D prescription drug plan, but those who had supplemental coverage and paid between $11.76 and $15.58 for a 30-day supply would pay substantially more under Part D.
Source: Gellad, WF, et al. Angiotensin receptor blockers on the formularies of Medicare drug plans. J Gen Intern Med. 2007 Aug;22(8):1172-5
More like this
- Part D’s underuse of generics wastes $1B per year
- ARBs already widely available on formularies for controlling hypertension
- How the Doughnut Hole Affects Prescription Fulfillment Decisions Involving Cardiovascular Medications For Medicare Part D Enrollees
- Fixed-Dose Triple-Combination Treatments In the Management of Hypertension
- Updated Guidelines Highlight Lack of Meds for Heart Failure
Our other journal
P&T Journal for September 2014
FEATURES
HEALTH CARE & LAW
Legal Risk Management Opportunities, Pharmacy Practice, and P&T Committees
Hospitals Struggle With ACA Challenges
Drug–Gene Interactions: Inherent Variability in Drug Maintenance Dose Requirements
Schizophrenia: Overview and Treatment Options
PIPELINE PLUS
Schizophrenia Therapy Options Increasing
DEPARTMENTS
MEDICATION ERRORS
Too Many Abandon the “Second Victims” of Medical Errors
PRESCRIPTION: WASHINGTON
New Controversy for 340B: OPA Rebuffs Ruling by Court
New Drugs/Drug News/New Medical Devices
Pharmaceutical Approval Update
DRUG FORECAST
Loxapine Inhalation Powder (Adasuve)

Paul Lendner ist ein praktizierender Experte im Bereich Gesundheit, Medizin und Fitness. Er schreibt bereits seit über 5 Jahren für das Managed Care Mag. Mit seinen Artikeln, die einen einzigartigen Expertenstatus nachweisen, liefert er unseren Lesern nicht nur Mehrwert, sondern auch Hilfestellung bei ihren Problemen.